반응식
CNC(=O)c1c(N)cccc1OC.Cc1nn(C)cc1Nc1cc(I)c(C(F)(F)F)cn1>C1COCCO1.CC(=O)O.CC(=O)O.CC1(C)c2cccc(P(c3ccccc3)c3ccccc3)c2Oc2c(P(c3ccccc3)c3ccccc3)cccc21.O=C([O-])[O-].[Cs+].[Cs+].[Pd]>CNC(=O)c1c(Nc2cc(Nc3cn(C)nc3C)ncc2C(F)(F)F)cccc1OC참가 물질
반응물 2
생성물 1
시약·촉매·용매 4
반응 조건
- 온도
- 100 °C
실험 절차
A suspension of [Reactants], N-(1,3-dimethyl-1H-pyrazol-4-yl)-4-iodo-5-(trifluoromethyl)pyridin-2-amine (2.63 g, 6.88 mmol), diacetoxypalladium (0.077 g, 0.34 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (0.398 g, 0.69 mmol) and cesium carbonate (4.48 g, 13.77 mmol) in dioxane (37 mL) was degassed with argon then stirred at 100 °C for 3 hours . The reaction mixture was concentrated to dryness, diluted with ethyl acetate (80 ml), washed with water (1 x 50 ml), brine, dried over magnesium sulfate and concentrated to afford an oil. The crude product was purified by flash chromatography on silica gel eluting with AcOet pure to remove impurities then 3 to 8% methanol in ethyl acetate. The solvent was evaporated to dryness to afford a foam which was dissolved in dichloromethane ( 12ml ). A solid was formed after a few minutes, which was filtered, dried .A white solid was obtained 2-(2-(1,3-dimethyl-1H-pyrazol-4-ylamino)-5-(trifluoromethyl)pyridin-4-ylamino)-6-methoxy- N-methylbenzamide (1.570 g, 52.5 %)
출처 및 근거
- ORD 기록
- ord-183f397304e242fab1c88325fcefdf27
- 출처 데이터셋
- 750 AstraZeneca ELN dataset
- 원본 링크
- 출처 보기
연결된 노트
불러오는 중…